top of page
The Professional Network for Healthcare Experts
FDA expands Truqap approval to PTEN-deficient metastatic hormone-sensitive prostate cancer
The biomarker-selected regimen adds an AKT inhibitor to abiraterone and prednisone for adults with newly diagnosed metastatic disease whose tumours show PTEN deficiency.
nuaxia
Aug 62 min read
FDA approves Pluvicto with androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer
The expanded indication moves radioligand therapy into an earlier stage of metastatic prostate cancer, providing an additional treatment option for eligible patients before progression to castration-resistant disease.
nuaxia
Aug 32 min read
bottom of page